Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind crossover trial of miglustat on nasal potential difference in cystic fibrosis (ΔF508 homozygous)
2006-002049-35Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of miglustat in cystic fibrosis (CF) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Change in nasal potential difference (NPD). Started May 2007; status: completed.
02
Drugs
miglustat
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2006-002049-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002049-35.